Tesamorelin GHRH peptide records at bookingpeptides
This engagement starts at the pituitary. The records connect growth-hormone release with visceral fat, then ask separately about insulin sensitivity.
GHRH receptor studies
Tesamorelin has its booking with the growth hormone-releasing hormone receptor, GHRH-R, on somatotroph cells in the anterior pituitary. Those cells make growth hormone. Activating the receptor stimulates the body’s own GH synthesis and pulsatile release, followed by increased production of IGF-1 in the liver.
The human pharmacology experiment examining GH and insulin sensitivity makes this chain tangible. The gap between receptor binding and downstream effects interests me: tesamorelin engages GHRH-R, while growth hormone and IGF-1 carry the signal onwards. Counting only the first receptor leaves much of the mechanism of action off the page.
What it is
Tesamorelin is a synthetic 44-amino-acid analogue of human GHRH. Its N-terminal trans-3-hexenoic acid modification resists DPP-IV cleavage, extending stability compared with native GHRH. It works through the growth-hormone axis, a different starting point from the incretin peptides.
The LiverTox monograph on tesamorelin records U.S. approval in 2010 for excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy. That remains its specific FDA-approved indication. General fat loss, anti-aging and other uses fall outside that indication.
THE ACCESS CATEGORY
A clinical gate, separate from the reading desk
For tesamorelin, mypromise.com identifies Promise Peptides, a U.S. telehealth service that now prescribes the medication. The prescriber's individual review can end in a refusal; a licensed U.S. clinician makes that decision. Only U.S. patients are considered, and the options differ with the patient's state and the treatment requested. A tesamorelin medication prepared by compounding has no FDA approval. Laboratory-labelled tesamorelin remains on sale for research; it is not patient medication.
Insulin sensitivity and diabetes
In 13 healthy men studied over 2 weeks, tesamorelin increased mean overnight GH by +0.5 µg/L and IGF-1 by 181 µg/L. Fasting glucose and insulin-stimulated glucose uptake were not significantly affected. The latter measurement examines how tissues respond to insulin.
For tesamorelin and diabetes, that population is an essential qualification: these were healthy men, followed briefly. I regard preservation of insulin sensitivity here as useful physiological information. It leaves the much larger question of long-term insulin resistance in people with diabetes unanswered.
The 52-week HIV programme reported glucose changes that were not clinically significant. Modest glucose perturbation remains a concern in people with prediabetes or dysglycaemia. Tesamorelin has no FDA indication for diabetes.
Abdominal fat measurements
Visceral fat sits around abdominal organs. In the JAMA trial of 50 antiretroviral-treated adults with HIV, the 6-month treatment effect on visceral fat was -42 cm², and the net change in hepatic lipid-to-water percentage was -2.9%. The precision of those measurements appeals to me: a particular deposit of fat, in a particular clinical setting.
The 2026 meta-analysis of five randomised trials in HIV-associated lipodystrophy reported mean differences of -27.71 cm² in visceral fat, -1.18 kg in trunk fat, -4.28% in hepatic fat fraction and +1.42 kg in lean body mass. These findings come from HIV-associated lipodystrophy populations; they do not establish general-population fat-loss effects.
Continuation and safety
In the 52-week programme, visceral-fat reduction was sustained at -18% versus baseline, and fat reaccumulated after discontinuation. That makes the duration of the intervention central to the result. I’d give the return of fat space beside its initial reduction.
The drug-safety reference assigns tesamorelin a LiverTox likelihood score of E, indicating an unlikely cause of clinically apparent liver injury. GH-axis stimulation also raises IGF-1; active malignancy is a labelled contraindication, and long-term oncologic safety data are limited. Tesamorelin is prohibited in sport under WADA category S2, in and out of competition.
The useful question for this compound is narrower than a generic peptide comparison: how does GHRH stimulation change visceral fat in the population actually studied? The receptor comparison makes the different starting point easy to see.